See every side of every news story
Published loading...Updated

Actithera Joins Radiopharmaceutical Boom with $75.5M Series A - Boston ...

OSLO, NORWAY AND CAMBRIDGE, MASSACHUSETTS, JUL 9 – Actithera secured $75.5 million in an oversubscribed Series A round led by M Ventures and others to prepare clinical development of its FAP-targeted cancer drug starting in 2026.

  • On July 9, 2025, Actithera, a radiopharmaceutical biotech firm headquartered in Oslo and Cambridge, successfully secured $75.5 million in a heavily subscribed Series A funding round.
  • The funding round was jointly led by M Ventures along with new leading investors specializing in life sciences, providing support for the clinical progression of the company’s primary candidate targeting fibroblast activation protein .
  • Actithera develops small-molecule radioligands designed to improve tumor targeting, extend tumor residence, and enable rapid clearance to reduce toxicity in radioligand therapies .
  • Dr. Andreas Goutopoulos explained that their goal was to apply principles from small-molecule drug development, focusing on structural and kinetic insights, to enhance the design of radiopharmaceutical therapies.
  • The funding will allow Actithera to advance clinical trials starting in 2026 across multiple oncology indications, reflecting growing investor confidence in radiopharmaceutical therapies.
Insights by Ground AI
Does this summary seem wrong?

12 Articles

All
Left
Center
5
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

biopharmadive.com broke the news in on Wednesday, July 9, 2025.
Sources are mostly out of (0)

You have read 1 out of your 5 free daily articles.

Join millions of well-informed readers who use Ground to compare coverage, check their news blindspots, and challenge their worldview.